Researchers track rare kidney disease to see how treatment holds up in real life
NCT ID NCT04982393
First seen Nov 01, 2025 · Last updated May 07, 2026 · Updated 26 times
Summary
This study follows 207 people with primary hyperoxaluria type 1 (PH1), a rare genetic condition that causes kidney stones and kidney damage. Researchers are watching how the disease naturally progresses and checking the long-term safety and effectiveness of the drug lumasiran in everyday use. No new treatments are being tested—just careful observation.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY HYPEROXALURIA TYPE 1 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Clinical Trial Site
Phoenix, Arizona, 85016, United States
-
Clinical Trial Site
Washington D.C., District of Columbia, 20010, United States
-
Clinical Trial Site
Boston, Massachusetts, 02115, United States
-
Clinical Trial Site
Rochester, Minnesota, 55905, United States
-
Clinical Trial Site
Cincinnati, Ohio, 45229, United States
-
Clinical Trial Site
Pittsburgh, Pennsylvania, 15213, United States
-
Clinical Trial Site
Dallas, Texas, 75390, United States
-
Clinical Trial Site
Houston, Texas, 77030, United States
-
Clinical Trial Site
Ghent, Belgium
-
Clinical Trial Site
Liège, Belgium
-
Clinical Trial Site
Hamilton, Ontario, Canada
-
Clinical Trial Site
Toronto, Ontario, Canada
-
Clinical Trial Site
Laurier, Quebec, Canada
-
Clinical Trial Site
Bordeaux, France
-
Clinical Trial Site
Lyon, France
-
Clinical Trial Site
Paris, France
-
Clinical Trial Site
Berlin, Germany
-
Clinical Trial Site
Cologne, Germany
-
Clinical Trial Site
Hamburg, Germany
-
Clinical Trial Site
Jerusalem, Israel
-
Clinical Trial Site
Orbassano, Torino, Italy
-
Clinical Trial Site
Milan, Italy
-
Clinical Trial Site
Verona, Italy
-
Clinical Trial Site
Amsterdam, Netherlands
-
Clinical Trial Site
Santa Cruz de Tenerife, Canary Islands, Spain
-
Clinical Trial Site
Barcelona, Spain
-
Clinical Trial Site
Las Palmas, Spain
-
Clinical Trial Site
Bern, Switzerland
-
Clinical Trial Site
London, England, United Kingdom
-
Clinical Trial Site
London, United Kingdom
Conditions
Explore the condition pages connected to this study.